GEN Exclusives

More »
New Products

Related to Partnership to Find Synergistic Compounds for RNA-Based Anticancer Drugs

    • DNA Reference Standard
    • Horizon Discovery
    • The Quantitative Multiplex DNA reference standard is intended for researchers assessing multiple biomarkers in a single assay using platforms such as next-generation sequencing. It can enable researchers to quantify a range of detection thresholds
    • HCS Station
    • Olympus
    • The scan^R 2.4 high-content screening station is based upon the IX3 inverted microscope frame. The updated screening station can now be incorporated with the fully automated IX83, combining a modular frame design with scan speed. This new system ca
    • Microarray Scanner
    • Agilent Technologies
    • The SureScan Dx microarray scanner is indicated for use in a clinical laboratory environment when measuring fluorescence signals of labeled DNA or RNA targets hybridized to microarrays used as part of a validated diagnostic assay. The system has be
    • Drug Screening Software
    • AB Sciex
    • MPX™ TF 1.0 software is designed to accelerate drug screening on the basis of accurate mass technology. With this software, throughput may be increased by as much as twofold by enabling the use of two parallel liquid chromatography streams. The abi
    • Electrophysiology Platform
    • Molecular Devices
    • The IonWorks Barracuda® Plus system is an automated patch-clamp system that is designed to produce wide assay windows and stable ionic currents, enabling protocols to probe the use-dependent nature of ion channel drug candidates. Use-dependent
  • Page 1 of 1 (6 items) 1 

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?